Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study

about

Baclofen in the Therapeutic of Sequele of Traumatic Brain Injury: Spasticity.

P2860

Q37409633-A61193FF-DD35-4C95-8125-A8BC0596A592

P2860

Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study

Item

http://www.wikidata.org/entity/Q36171531

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Cost analysis of glatiramer ac ...... h spasticity: the Escala study

@ast

Cost analysis of glatiramer ac ...... h spasticity: the Escala study

@en

type

Item

label

Cost analysis of glatiramer ac ...... h spasticity: the Escala study

@ast

Cost analysis of glatiramer ac ...... h spasticity: the Escala study

@en

prefLabel

Cost analysis of glatiramer ac ...... h spasticity: the Escala study

@ast

Cost analysis of glatiramer ac ...... h spasticity: the Escala study

@en

P1476

Cost analysis of glatiramer ac ...... h spasticity: the Escala study

@en

P2093

José Meca-Lallana

http://www.w3.org/2001/XMLSchema#string

Laura García-Bujalance

http://www.w3.org/2001/XMLSchema#string

Rainel Sánchez-de la Rosa

http://www.w3.org/2001/XMLSchema#string

P2860

Defining the clinical course of multiple sclerosis: Results of an international survey

Benefit–Risk Analysis of Glatiramer Acetate for Relapsing-Remitting and Clinically Isolated Syndrome Multiple Sclerosis

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

Multiple sclerosis: side effects of interferon beta therapy and their management

Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.

Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.

Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on data a Balkan country in socioeconomic transition.

A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.

Developing guidance for budget impact analysis.

Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference.

P2888

s13561-015-0066-2

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13561-015-0066-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

282944814

http://www.w3.org/2001/XMLSchema#string

P6179

1045172748

http://www.w3.org/2001/XMLSchema#string

P698

26475277

http://www.w3.org/2001/XMLSchema#string

P932

4608957

http://www.w3.org/2001/XMLSchema#string

Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study

about

P2860

P2860

Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P6179

P698

P932